next biotech multi bagger, page-9

G'day supertramp, 

I agree that former TIS holders(of which I am one) have held their enthusiasm for a successful VLU trial in check given past experience. However, I have been extremely encouraged by the data generated and presented so far, the expertise of FTT's board and consultants and the administration of the trial itself. Dr Ros Wilson, FTT CEO in her August 2018 Broker Presentation "A Potential Game Changer in Advanced Wound Care" made the salient point that the only FDA approved medicine for wound healing (for Diebetic Foot Ulcers) actually occurred in 1997 (Regranex). Can you think of any other area of medicine where no significant discoveries or significant improvements have occurred, or new medicinal products come onto the market in the last twenty years! I remain quietly confident that (this time) Factor Therapeutics will achieve success in this VLU trial and I eagerly await the results readout in mid November 2018. Regards, Goggo DYOR